HONG KONG, Oct. 18, 2022 /PRNewswire/ Future salad, a Hong Kong food-tech company established in 2020 has been expanding into the overseas market. During this time, it has been enjoyed and
Celregen Therapeutics signed a $100 million agreement to in-license China rights for a novel therapy that uses induced Pluripotent Stem Cells to repair bullous keratopathy.